BioSpace News Archive

Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the fourth quarter and full-year ended December 31, 2022, and provided a corporate update.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced that it has completed key tech transfer, scale up and manufacturing activities required to initiate a global, multicenter Phase 3 registrational trial investigating the combination of PDS0101 and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in the fourth quarter of 2023.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) today announces it has signed an agreement to expand the INSIGHT-003 trial evaluating the combination of eftilagimod alpha (“efti”), a soluble LAG-3 protein and first-in-class MHC class II agonist, in conjunction with standard-of-care combination of anti-PD-1 therapy and chemotherapy in 1st line non- small cell lung cancer (1L NSCLC).

Avalyn Pharma Inc. today reported top-line results from the company’s Phase 1 trial for AP02 (inhaled nintedanib).

aTyr Pharma, Inc. announced the publication of a review article, titled, “Efzofitimod: a novel anti-inflammatory agent for sarcoidosis,” in the peer-reviewed journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases.

CANbridge Pharmaceuticals, Inc., a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced financial results for the twelve months ended 2022 and corporate update.

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced financial results for the full-year ended December 31, 2022, and recent corporate highlights.

GenScript Biotech, the world’s leading biotech company, announces its annual results as of December 31, 2022.